Novartis strengthens executive committee further
Novartis this week announced changes to its senior leadership team to support the implementation of its strategic priorities. These changes include the appointment of Shannon Klinger in the elevated and expanded role of chief ethics, risk, and compliance officer, effective April 1.
Related articles
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
PremiumShadow AI: Another element of TPRM
Companies may face significant financial and legal risks if they fail to vet suppliers and third parties over their use of unauthorized AI and how the technology may use and share their corporate data.
-
OpinionBeyond the Binder: Policy governance in practice
Most compliance professionals have faced it: a regulator or client requests a policy, and several slightly different “final” versions appear. The issue often stems from reactive, siloed work without a unified governance framework.